You are here:   Blog
Register   |  Login

The Wellness Blog with Elaine Moore

Blogs by Date

Elaine Moore's Blog
Elaine Moore
300 82115 12/5/2020

Blogs by Category


Main Blog


LDN and Ketamine COVID-19 Trial

By Elaine Moore on 5/8/2020

In severe cases of infection with the SARS-CoV-2 virus, the cause of COVID-19, an autoimmune reaction is responsible for deadly symptoms. In stages 2b, late pulmonary effects are seen, and in stage 3 hyperinflammation with cytokine storms occur.

Severe cases of this disease are associated with low lymphocyte counts and high levels of the cytokine, interleukin-6 (IL-6). As immunomodulators when used in low doses, both low dose naltrexone (LDN) and ketamine reduce IL-6 production, halting COVID-19 disease progression. In addition, LDN is known to have antiviral properties.

The trial, Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19 (SINK COVID-19) is being conducted at William Beaumonts Hospitals and information on the trial can be found at


Elaine A. Moore and Samantha Wilkinson. The Promise of Low Dose Naltrexone. McFarland Publishing. 2009.

Graves' Disease and Autoimmune Disease Education
Copyrighted by Elaine Moore © 2008-2025   |   All Rights Reserved. All writing and images copyrighted.
Copyright Notices and Disclaimers  Designed & Developed by VESWEB Using DNN 2008